Genprex Inc. has announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent covering the use of its lead drug candidate, Reqorsa® Gene Therapy, in combination with PD-L1 antibodies, such as Tecentriq®. Additionally, the European Patent Office has issued a Notice of Allowance for a patent covering the use of REQORSA in combination with PD-1 antibodies. Both patents will expire in 2037 at the earliest. These developments enhance Genprex's intellectual property estate for its oncology program involving immune checkpoint inhibitors, specifically applicable to the Acclaim-3 clinical trial. Furthermore, Genprex is pursuing additional patent applications in Europe, Canada, Brazil, China, and Israel, which, if granted, would also support the Acclaim-3 trial.
Winning Trades
Share your positions with us! This is a column where you can find the winning trades of our fellow tigers. There probably are a few potential opportunities that you may have overlooked.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments